Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes MOST POPULAR FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma March 12, 2021 New study supports extending cervical screening intervals for people who test... May 31, 2022 EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... June 26, 2019 Load more HOT NEWS Today is Veterans Day The Appraisal – Scientific disruption: what is it, and do we... Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer When Prenatal DNA Tests Point to Cancer
